LivaNova (NASDAQ:LIVN) Price Target Lowered to $64.00 at Needham & Company LLC

LivaNova (NASDAQ:LIVN) had its price target reduced by Needham & Company LLC from $75.00 to $64.00 in a research report sent to investors on Wednesday morning,Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.

A number of other analysts also recently weighed in on LIVN. StockNews.com upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 14th. Robert W. Baird lifted their price target on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Mizuho decreased their price target on LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research note on Thursday, October 31st. Finally, Wolfe Research downgraded LivaNova from an “outperform” rating to a “peer perform” rating in a research note on Wednesday. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $64.20.

LivaNova Trading Down 0.6 %

Shares of LIVN stock opened at $41.45 on Wednesday. The business’s 50 day moving average is $47.65 and its two-hundred day moving average is $49.56. LivaNova has a twelve month low of $40.37 and a twelve month high of $64.47. The company has a market capitalization of $2.25 billion, a P/E ratio of 98.69 and a beta of 1.00. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46.

Insider Activity at LivaNova

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the business’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total transaction of $63,737.50. Following the completion of the sale, the director now owns 7,522 shares of the company’s stock, valued at approximately $383,546.78. The trade was a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.27% of the company’s stock.

Institutional Investors Weigh In On LivaNova

A number of institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. grew its position in LivaNova by 17.1% during the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock valued at $70,000 after acquiring an additional 219 shares during the period. Summit Investment Advisors Inc. grew its position in LivaNova by 1.7% during the fourth quarter. Summit Investment Advisors Inc. now owns 16,846 shares of the company’s stock valued at $780,000 after acquiring an additional 289 shares during the period. Atria Investments Inc grew its position in LivaNova by 6.2% during the third quarter. Atria Investments Inc now owns 5,653 shares of the company’s stock valued at $297,000 after acquiring an additional 331 shares during the period. State of Alaska Department of Revenue grew its position in LivaNova by 7.3% during the third quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company’s stock valued at $328,000 after acquiring an additional 425 shares during the period. Finally, Xponance Inc. boosted its position in shares of LivaNova by 6.1% in the fourth quarter. Xponance Inc. now owns 7,762 shares of the company’s stock worth $359,000 after buying an additional 445 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.